SUNNYVALE, Calif., May 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that Timothy G. Whitten, the company's senior vice president of Commercial Operations and Development, is scheduled to present a corporate overview at the Needham & Company Fourth Annual Biotechnology Conference on Thursday, May 26, 2005, at 2:00 p.m. EDT. This event will be held at the New York Palace Hotel in New York City.
To access the live audio broadcast or the subsequent archived recording, log on to http://www.pharmacyclics.com . The archived version of the webcast will be available online for one month.
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and atherosclerosis. The company's products are rationally designed, ring-shaped small molecules called texaphyrins that are designed to selectively target and disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. More information about the company, its technology, and products in development can be found on its website at www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
SOURCE Pharmacyclics, Inc.
Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or Carolyn Bumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics, Inc.
Copyright (C) 2005 PR Newswire. All rights reserved.
News Provided by COMTEX